Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sarepta Therapeutics (NQ: SRPT ) 143.78 -3.12 (-2.12%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 693,812 Open 147.57 Bid (Size) 143.73 (1) Ask (Size) 143.78 (2) Prev. Close 146.90 Today's Range 143.62 - 147.85 52wk Range 55.25 - 173.25 Shares Outstanding 93,148,652 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today July 18, 2024 Via Benzinga SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know. July 17, 2024 The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. Via InvestorPlace Performance YTD +49.44% +49.44% 1 Month +22.35% +22.35% 3 Month +23.36% +23.36% 6 Month +23.10% +23.10% 1 Year +35.76% +35.76% More News Read More Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' July 17, 2024 Via Benzinga Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives July 17, 2024 From Cassava Sciences, Inc. Via GlobeNewswire Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today July 04, 2024 Via Benzinga Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts July 01, 2024 Via Benzinga Looking At Sarepta Therapeutics's Recent Unusual Options Activity June 26, 2024 Via Benzinga After a Big Win, Is Sarepta Therapeutics Stock a Buy? July 06, 2024 Via The Motley Fool Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? July 04, 2024 Via The Motley Fool Exposures Product Safety 1 Soaring Growth Stock to Buy and Hold for 10 Years July 03, 2024 Via The Motley Fool Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 28, 2024 From Sarepta Therapeutics, Inc. Via Business Wire Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. June 26, 2024 Via The Motley Fool Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years June 24, 2024 Via Benzinga Sarepta Therapeutics Scores 90-Plus RS Rating On Muscular Dystrophy Approval June 24, 2024 Via Investor's Business Daily Micron To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Monday June 24, 2024 Via Benzinga DraftKings And Dell Were Among The 10 Biggest Large Cap Stock Gainers Last Week (June 16-June 22): Are These In Your Portfolio? June 23, 2024 Via Benzinga Google Parent Alphabet At All-Time High, In Stock Spotlight: See New Names On IBD 50, Stock Spotlight And More June 21, 2024 Via Investor's Business Daily Growth Stocks Leave Value Stocks In The Dust: 4 Reasons For Biggest Monthly Lead In Over A Year June 21, 2024 Via Benzinga Nasdaq Moves Lower; FactSet Research Posts Upbeat Earnings June 21, 2024 Via Benzinga Why Kaival Brands Innovations Shares Are Trading Lower By 47%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 21, 2024 Via Benzinga Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty June 21, 2024 Via Benzinga Stocks Stall As Chip Sector Struggles To Rebound; Dollar Eyes 7-Week Peak, Gold, Bitcoin Retreat: What's Driving Markets Friday? June 21, 2024 Via Benzinga Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says June 21, 2024 Via Benzinga Exposures Product Safety Gold Down 1%; CarMax Shares Gain After Q1 Earnings June 21, 2024 Via Benzinga Sarepta Therapeutics Stock Soars on FDA Approval June 21, 2024 Via MarketBeat Exposures Product Safety Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
